Cetera Advisors LLC Boosts Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Cetera Advisors LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,083 shares of the company’s stock after purchasing an additional 1,856 shares during the quarter. Cetera Advisors LLC’s holdings in IDEXX Laboratories were worth $5,444,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of IDXX. Cetera Investment Advisers lifted its position in shares of IDEXX Laboratories by 294.8% during the first quarter. Cetera Investment Advisers now owns 20,129 shares of the company’s stock worth $10,868,000 after purchasing an additional 15,030 shares during the last quarter. PGGM Investments lifted its position in shares of IDEXX Laboratories by 17.2% during the first quarter. PGGM Investments now owns 3,037 shares of the company’s stock worth $1,640,000 after purchasing an additional 446 shares during the last quarter. Atria Investments Inc lifted its position in shares of IDEXX Laboratories by 11.5% during the first quarter. Atria Investments Inc now owns 4,549 shares of the company’s stock worth $2,456,000 after purchasing an additional 470 shares during the last quarter. Swedbank AB bought a new stake in shares of IDEXX Laboratories during the first quarter worth $21,013,000. Finally, LRI Investments LLC bought a new stake in shares of IDEXX Laboratories during the first quarter worth $57,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 1.9 %

IDXX traded down $9.21 on Friday, hitting $468.63. The company had a trading volume of 827,133 shares, compared to its average volume of 527,028. The stock has a fifty day moving average price of $489.02 and a 200-day moving average price of $514.86. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The stock has a market capitalization of $38.70 billion, a price-to-earnings ratio of 45.37, a P/E/G ratio of 3.91 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. Analysts predict that IDEXX Laboratories, Inc. will post 11 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the sale, the director now owns 161 shares in the company, valued at $87,068.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.11% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on IDXX. Barclays decreased their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. BTIG Research initiated coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Morgan Stanley cut their price target on IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Finally, William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $582.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.